SciELO - Scientific Electronic Library Online

 
vol.60 número1Eficacia del ultrasonido endobronquial con aspiración por aguja fina en el diagnóstico de lesiones hiliares y mediastinales índice de autoresíndice de assuntospesquisa de artigos
Home Pagelista alfabética de periódicos  

Serviços Personalizados

Journal

Artigo

Indicadores

  • Não possue artigos citadosCitado por SciELO

Links relacionados

  • Não possue artigos similaresSimilares em SciELO

Compartilhar


Revista Cubana de Medicina

versão impressa ISSN 0034-7523versão On-line ISSN 1561-302X

Resumo

RAMON CONCEPCION, Iván et al. Quality of life in patients suffering from bone metastasis due to prostate cancer treated with zoledronic acid. Rev cubana med [online]. 2021, vol.60, n.1, e1354.  Epub 25-Fev-2021. ISSN 0034-7523.

Introduction:

Zoledronic Acid improves the quality of life of patients suffering from prostate cancer.

Objectives:

To assess the health-related quality of life using EORTC QLQ-BM22 questioner in patients suffering from prostate cancer, treated with zoledronic acid.

Method:

A prospective-descriptive study was carried out in 71 patients suffering from prostate cancer involving bones, with ages ranging between 18 and 80 years, and who were treated in the oncology service at Hermanos Ameijeiras Hospital. The ECOG was less than 3, life expectancy> 6 months, and follow-up of at least twelve months. Zoledronic acid was administered every 21-28 days. The visual analog scale and EORTC QLQ-BM22 module were applied.

Results:

The patients had median age of 71 years, Gleason ≥ 8: in 57.7% of the patients, PSA at diagnosis ≥ 20 ng / mL: 70.4%, ECOG 1: 67.6%, and stage IV as initial presentation: 50.7%. Bone metastases without visceral intake: 84.5%, in vertebrae 36.6%, <3 sites 66.2%, and blast bone metastases 60.6%. Skeletal events related to zoledronic acid before 7.9% (fracture), and after 5.6% (anti-allergic radiotherapy). At twelve months, according to the visual analog scale, a complete response was achieved, 71%, and a partial response, 29% (p <0.05). After the application of EORTC QLQ-BM22 module, a significant decrease was found in both the symptom and functional scales, regardless of other factors.

Conclusions:

Specific treatments for prostate cancer combined with zoledronic significantly improve pain and health-related quality of life in patients with bone metastases.

Palavras-chave : quality of life; Zoledronic acid; bone metastases; prostate cancer.

        · resumo em Espanhol     · texto em Espanhol     · Espanhol ( pdf )